ReviewIntensive care medicine2012
The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.
Review in Intensive care medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Plasma sRAGE is independently associated with increased mortality in ARDS: a meta-analysis of individual patient data.Intensive care medicine · 2018Pooled it
- Perioperative Open-lung Approach, Regional Ventilation, and Lung Injury in Cardiac Surgery.Anesthesiology · 2020Trial
- Structural and molecular principles of DAMP biology.Nature structural & molecular biology · 2026Review
- Eosinophil count combined with routine indicators enhances early risk prediction value for ARDS in ICU patients: a retrospective cohort study.Open medicine (Warsaw, Poland) · 2026Article
- Correlation between stress hyperglycemia ratio and risk of acute respiratory distress syndrome in patients with sepsis: a MIMIC-IV cohort study.Scientific reports · 2025Article
- A mouse model of E-cigarette or vaping product use-associated lung injury (EVALI) induced by nose-only exposure to aerosolized vitamin E acetate and associated macrophage dysfunction.Respiratory research · 2025Article
- Primary Graft Dysfunction in Lung Transplantation: An Overview of the Molecular Mechanisms.International journal of molecular sciences · 2025Review
- Diabetes mellitus-driven pulmonary injury: multidimensional mechanisms linking metabolic dysregulation to gut-lung axis and promising therapies.Frontiers in pharmacology · 2025Review
- Cell Proliferation and Apoptosis-Key Players in the Lung Aging Process.International journal of molecular sciences · 2024Review
- Early serum biomarkers to characterise different phenotypes of primary graft dysfunction after lung transplantation: a systematic scoping review.ERJ open research · 2024Article
- Rapidly improving ARDS differs clinically and biologically from persistent ARDS.Critical care (London, England) · 2024Observational
- Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS).Respiratory research · 2024Review
- hWJMSCs inhibit inflammation and apoptosis in an ARDS cell model.Journal of Taibah University Medical Sciences · 2023Article
- Effects of sevoflurane on lung epithelial permeability in experimental models of acute respiratory distress syndrome.Journal of translational medicine · 2023Article
- Preventative Management of Sepsis-Induced Acute Respiratory Distress Syndrome in the Geriatric Population.Cureus · 2023Review
- Receptor for Advanced Glycation End-Products Promotes Activation of Alveolar Macrophages through the NLRP3 Inflammasome/TXNIP Axis in Acute Lung Injury.International journal of molecular sciences · 2022Article
- Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice.JCI insight · 2022Article
- Advanced development and mechanism of sepsis-related acute respiratory distress syndrome.Frontiers in medicine · 2022Review
- Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.International immunopharmacology · 2021Review
- Discovering Causal Mechanistic Pathways in Sepsis-associated Acute Respiratory Distress Syndrome.American journal of respiratory and critical care medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
The receptor for advanced glycation end products (RAGE) is a pattern-recognition receptor and evolutionary member of the immunoglobulin superfamily that is involved in the host response to infection, injury, and inflammation. It exists in two forms: membrane-bound and soluble forms (sRAGE). RAGE recognizes a variety of ligands and, via a receptor-driven signaling cascade, activates the transcription factor NF-κB, leading to the expression of proinflammatory cytokines. The soluble form, sRAGE, is a decoy receptor and competitively inhibits membrane RAGE activation. RAGE is constitutively expressed abundantly in the lung under basal conditions. This expression is enhanced during inflammatory states such as with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). This review summarizes the characteristics of RAGE, RAGE isoforms, RAGE ligands, and signaling pathways in the pathogenesis of ALI and ARDS. Additionally, the review explores the potential of RAGE as an important therapeutic target in ALI/ARDS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.